Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-04-20
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 147
- Registration Number
- NCT04851119
- Locations
- πΊπΈ
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
πΊπΈChildren's Hospital of Alabama, Birmingham, Alabama, United States
πΊπΈChildren's Hospital Los Angeles, Los Angeles, California, United States
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
- Conditions
- Interventions
- Procedure: Biospecimen CollectionDrug: CarboplatinDrug: EtoposideBiological: FilgrastimDrug: IfosfamideProcedure: Magnetic Resonance ImagingDrug: MesnaBiological: PegfilgrastimProcedure: Peripheral Blood Stem Cell TransplantationOther: Questionnaire AdministrationRadiation: Radiation TherapyProcedure: Second-Look SurgeryDrug: Thiotepa
- First Posted Date
- 2020-12-24
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 160
- Registration Number
- NCT04684368
- Locations
- πΊπΈ
University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States
πΊπΈDartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire, United States
π¦πΊSydney Children's Hospital, Randwick, New South Wales, Australia
Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)
- Conditions
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyBiological: DinutuximabProcedure: FDG-Positron Emission TomographyRadiation: Iobenguane I-123Drug: IrinotecanDrug: IsotretinoinProcedure: Magnetic Resonance ImagingProcedure: Multigated Acquisition ScanBiological: SargramostimDrug: Temozolomide
- First Posted Date
- 2020-05-12
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 41
- Registration Number
- NCT04385277
- Locations
- πΊπΈ
Nationwide Children's Hospital, Columbus, Ohio, United States
πΊπΈDana-Farber Cancer Institute, Boston, Massachusetts, United States
πΊπΈBaylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
- Conditions
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionProcedure: Bone ScanDrug: CarboplatinProcedure: Computed TomographyDrug: CyclophosphamideDrug: DoxorubicinDrug: EtoposideDrug: IfosfamideDrug: IrinotecanProcedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyRadiation: Radiation TherapyProcedure: Surgical ProcedureProcedure: Transabdominal UltrasoundDrug: TopotecanDrug: VincristineProcedure: X-Ray Imaging
- First Posted Date
- 2020-03-26
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 221
- Registration Number
- NCT04322318
- Locations
- πΊπΈ
Tufts Children's Hospital, Boston, Massachusetts, United States
πΊπΈDana-Farber Cancer Institute, Boston, Massachusetts, United States
πΊπΈUMass Memorial Medical Center - University Campus, Worcester, Massachusetts, United States
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Conditions
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationDrug: AsparaginaseDrug: Asparaginase Erwinia chrysanthemiProcedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyBehavioral: Cogstate Assessment BatteryProcedure: Computed TomographyDrug: CytarabineDrug: EtoposideDrug: Dexrazoxane HydrochlorideDrug: Daunorubicin HydrochlorideOther: Fludeoxyglucose F-18Drug: Gemtuzumab OzogamicinDrug: Gilteritinib FumarateDrug: Liposome-encapsulated Daunorubicin-CytarabineDrug: MethotrexateProcedure: Magnetic Resonance ImagingDrug: Mitoxantrone HydrochlorideProcedure: Positron Emission TomographyDrug: Therapeutic Hydrocortisone
- First Posted Date
- 2020-03-03
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 1400
- Registration Number
- NCT04293562
- Locations
- πΊπΈ
Children's Hospital of Alabama, Birmingham, Alabama, United States
πΊπΈUSA Health Strada Patient Care Center, Mobile, Alabama, United States
πΊπΈChildren's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2020-02-06
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 60
- Registration Number
- NCT04258943
- Locations
- πΊπΈ
Seattle Children's Hospital, Seattle, Washington, United States
πΊπΈRiley Hospital for Children, Indianapolis, Indiana, United States
πΊπΈChildren's Specialty Center of Nevada II, Las Vegas, Nevada, United States
Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation
- First Posted Date
- 2019-12-18
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 10
- Registration Number
- NCT04203316
- Locations
- πΊπΈ
Children's Hospital of Alabama, Birmingham, Alabama, United States
πΊπΈArkansas Children's Hospital, Little Rock, Arkansas, United States
πΊπΈChildren's Hospital Colorado, Aurora, Colorado, United States
A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2019-12-11
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 35
- Registration Number
- NCT04195399
- Locations
- πΊπΈ
Rady Children's Hospital - San Diego, San Diego, California, United States
πΊπΈUCSF Medical Center-Mission Bay, San Francisco, California, United States
πΊπΈChildren's Hospital Colorado, Aurora, Colorado, United States
Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2019-11-12
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 16
- Registration Number
- NCT04158739
- Locations
- πΊπΈ
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States
πΊπΈSaint Jude Children's Research Hospital, Memphis, Tennessee, United States
πΊπΈChildren's Hospital of Alabama, Birmingham, Alabama, United States
Inherited Genetic Susceptibility in Langerhans Cell Histiocytosis (LCH)
- Conditions
- Interventions
- First Posted Date
- 2019-09-24
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 647
- Registration Number
- NCT04100408
- Locations
- πΊπΈ
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States